Prof. Michel Hermans

Current position

• Senior Consultant & Assistant Professor, Endocrinology & Nutrition,
Cliniques universitaires St-Luc, Université catholique de Louvain, Brussels, Belgium
• Senior lecturer (diabetes, sports nutrition, Louvain University Medical School).

Scientific training

• 1984 Medical degree - Louvain University Medical School, Brussels
• 1992 Specialist in Internal Medicine
• 1997 Medical degree - Louvain University Medical School, Brussels
• 1994 - 1995 Visiting Fellow - Diabetes Research Laboratories, Nuffield Department of Clinical Medicine,
University of Oxford Honorary Senior Registrar - Radcliffe Infirmary, Oxford, UK
• 2000 Diploma in Natural Sciences - Open University, Milton Keynes, UK
• 2003 Diploma in Earth Sciences - - Open University, Milton Keynes, UK
Diploma in Human Geography & Environment - Open University, Milton Keynes, UK
• 2005 Postgraduate Certificate in Social Sciences - Open University, Milton Keynes, UK

Professionnal associations

• Belgian Society of Internal Medicine
• Association Belge du Diabète
• Association de Langue Française pour l’Etude du Diabète et des Maladies Métaboliques
• American Diabetes Association
• Metabolic Syndrome Institute

Publications (selection)

• LevyJC, Matthews DR, Hermans MP. Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program. Diabetes Care 21:  2191-2192, 1998.
• Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia 42: 678-687, 1999.
• Buysschaert M, Hermans MP. Glycaemic and blood pressure controls achieved in a cohort of 318 patients with type 2 diabetes. Acta Clin Belg 54: 328-333, 1999 .
• Buysschaert M, Dramais AS, Wallemacq PE, Hermans MP. Hyperhomocysteinemia in type 2 diabetes. Relationship to macroangiopathy, nephropathy, and insulin resistance. Diabetes Care 23 :1816-1822, 2000.
• Buysschaert M, Jamart J, Dramais AS, Wallemacq P, Hermans MP. Micro- and macrovascular complications and hyperhomocysteinemia in type 1 diabetic patients. Diabetes Metab 27: 655-9, 2001.
• Buysschaert M, Hermans MP. Hyperhomocysteinaemia and macroangiopathy in type 2 diabetes (response to Chan et al.) Diabetes Care 24: 1124-25, 2001.
• Hermans MP, Buysschaert M, Dumont C. Clinical, biophysical and biochemical variables from African-heritage subjects with type 2 diabetes. Acta Clin Belg 57: 134-141, 2002.
• Hermans MP. Diabetes in ethnic minorities. In: Clinical Implications of Belgian Diabetes Research. P. Lefèbvre and I De Leeuw, eds. Belgian Diabetes Study Group, pp 63-66, 2004.
• Hermans MP, Pepersack TM, Godeaux LH, Beyer I, Turc AP. Prevalence and determinants of impaired glucose metabolism in frail elderly patients. The Belgian Elderly Diabetes Survey (B.E.D.S.). J Gerontol A Biol Sci Med Sci. 60: 241-247, 2005.
• Hermans MP, Buysschaert M. The Treat-To-Target paradigm: a cross-sectional survey of current therapies and achieved metabolic control in 800 type 2 diabetic patients. Acta Clinica Belgica 60: 79-85, 2005.
• Selvais P, Hermans M. Characterization of type 2 diabetes mellitus in first generation Italian migrants to Belgium. Acta Clin Belg. 60: 362-368, 2005.
• Hermans MP, Gala J-L, Buysschaert M. MTHFR C677T polymorphism confers a high risk for stroke to both homozygous and heterozygous T allele carriers with type 2 diabetes. Diabetic Med 23: 529-536, 2006.
• Lienart D, Preumont V, Alexopoulo O, Donckier J, Colson A, Hermans MP, Buysschaert M. Metabolic (glycaemic, lipidic) and blood pressure control in 101 type 2 diabetic patients on first admission to diabetes centres. Acta Clin Belg 61: 127-133, 2006.
• Hermans MP, Ahn SA, Rousseau MF. The non-HDL-C/HDL-C ratio provides cardiovascular risk stratification similar to the ApoB/ApoA1 ratio in diabetics: comparison with reference lipid markers. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 1: 23-28, 2007.
• Buysschaert M, Preumont V, Hermans MP. Hyperhomocysteinemia and diabetic macroangiopathy: guilty or innocent bystander ? A literature review of the current dilemna. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 1: 53-59, 2007.
• Hermans M. Diabetes and the endothelium. Acta Clin Belg 62: 97-101, 2007.
• Hermans M. Diabetic macro- and microvascular disease in type 2 diabetes. Diabetes Vasc Dis Res 4 (Suppl 2): 7-11, 2007.
• Kitoga M, Pasquet A, Preumont V, Kefer J, Hermans MP, Vanoverschelde JL, Butsschaert M. Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents. Diabetes Metab 34;62-7,2008.
• Hermans MP, Ahn SA, Gruson D, Rousseau MF. The metabolic syndrome phenotype is associated with raised circulating big endothelin-1 independently of coronary artery disease in type 2 diabetes. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 1: 229-237, 2007.
• Dehout F, Haumont S, Gaham N, Amoussou-Guenou KD, Hermans MP. Metabolic syndrome in Bantu subjects with type 2 diabetes from sub-Saharan extraction: prevalence, gender differences and HOMA-hyperbolic product. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2:5-11,2008.
• Munoko TN, Hermans MP. Phenotypic characterization of 1st generation Maghrebian migrants with type 2 diabetes. A gender-based comparison with a reference North-Caucasian Belgian cohort. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2;115-24,2008.
• Hermans MP, Ahn SA, Rousseau MF Neurohormonal biomarkers and UKPDS stroke risk in type 2 diabetic women on primary cardiovascular prevention. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2;93-8,2008.
• Ducobu J, Scheen A, Van Gaal L, Velkeniers B, Hermans MP. Belgian Expert opinion: how to reduce the residual risk in atherogenic dyslipidemic patients: place of fibrates. Acta Cardiol 63;235-48,2008.

Research

Early research were devoted to studying beta-cell biophysics and stimulus-secretion coupling.